BR112022003759A2 - Método e uso de pnpp-19 para prevenção e tratamento de doenças oculares - Google Patents

Método e uso de pnpp-19 para prevenção e tratamento de doenças oculares

Info

Publication number
BR112022003759A2
BR112022003759A2 BR112022003759A BR112022003759A BR112022003759A2 BR 112022003759 A2 BR112022003759 A2 BR 112022003759A2 BR 112022003759 A BR112022003759 A BR 112022003759A BR 112022003759 A BR112022003759 A BR 112022003759A BR 112022003759 A2 BR112022003759 A2 BR 112022003759A2
Authority
BR
Brazil
Prior art keywords
pnpp
treatment
eye diseases
prevention
glaucoma
Prior art date
Application number
BR112022003759A
Other languages
English (en)
Portuguese (pt)
Inventor
Da Silva Cunha Junior Armando
Nunes Da Silva Carolina
Max Gross Gerhard
Francisco De Paula Junior Iron
Fernanda Nunes Dourado Lays
Elena De Lima Perez Garcia Maria
Gustavo Sampaio Lacativa Paulo
Villani Borges Da Silva Perla
Original Assignee
Biozeus Desenvolvimento De Produtos Biofarmaceuticos S A
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biozeus Desenvolvimento De Produtos Biofarmaceuticos S A, Univ Minas Gerais filed Critical Biozeus Desenvolvimento De Produtos Biofarmaceuticos S A
Publication of BR112022003759A2 publication Critical patent/BR112022003759A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112022003759A 2019-09-03 2020-09-01 Método e uso de pnpp-19 para prevenção e tratamento de doenças oculares BR112022003759A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962895252P 2019-09-03 2019-09-03
US17/008,794 US20210060125A1 (en) 2019-09-03 2020-09-01 METHOD AND USE OF PnPP-19 FOR PREVENTING AND TREATING EYE DISEASES
PCT/BR2020/050349 WO2021042193A1 (en) 2019-09-03 2020-09-01 Method and use of pnpp-19 for preventing and treating eye diseases

Publications (1)

Publication Number Publication Date
BR112022003759A2 true BR112022003759A2 (pt) 2022-05-31

Family

ID=74682721

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003759A BR112022003759A2 (pt) 2019-09-03 2020-09-01 Método e uso de pnpp-19 para prevenção e tratamento de doenças oculares

Country Status (8)

Country Link
US (1) US20210060125A1 (https=)
EP (1) EP4025234A4 (https=)
JP (1) JP2022547231A (https=)
KR (1) KR20220084011A (https=)
CN (1) CN114302734A (https=)
BR (1) BR112022003759A2 (https=)
CA (1) CA3147704A1 (https=)
WO (1) WO2021042193A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024168415A1 (en) * 2023-02-17 2024-08-22 Biozeus Biopharmaceutical S.A. Topical peptide formulation for the treatment of sexual dysfunction
WO2025133214A1 (en) 2023-12-21 2025-06-26 Novaliq Gmbh Ophthalmic polypeptide compositions for the treatment of posterior eye disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005097137A (ja) * 2003-09-22 2005-04-14 Tokyoto Igaku Kenkyu Kiko 糖尿病性網膜症の予防又は治療剤
JP2011219412A (ja) * 2010-04-09 2011-11-04 Saisentan Igaku Kenkyusho:Kk 緑内障の視野改善治療薬
US8759298B2 (en) * 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
MX362058B (es) * 2012-08-20 2019-01-07 Univ Federal De Minas Gerais Ufmg Péptido pntx(19) sintético, composición farmacéutica y uso.
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
BR102014010268B1 (pt) * 2014-04-29 2021-12-28 Universidade Federal De Minas Gerais - Ufmg Uso do peptídeo sintético pntx-19 para tratamento de dor
WO2017068388A2 (pt) * 2015-09-18 2017-04-27 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor

Also Published As

Publication number Publication date
JP2022547231A (ja) 2022-11-10
US20210060125A1 (en) 2021-03-04
CN114302734A (zh) 2022-04-08
CA3147704A1 (en) 2021-03-11
EP4025234A1 (en) 2022-07-13
WO2021042193A1 (en) 2021-03-11
KR20220084011A (ko) 2022-06-21
EP4025234A4 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
MX2018014573A (es) Vacuna contra el virus del zika.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
CO2020014563A2 (es) Uso de clorhidrato de pilocarpina para el tratamiento de condiciones oculares
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
BR112018012876A2 (pt) bisturi oftálmico e métodos de uso
MX2021015853A (es) Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida.
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CL2022002566A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
BR112022000229A2 (pt) Composição para uso no tratamento da perda de cabelo
BR112022003759A2 (pt) Método e uso de pnpp-19 para prevenção e tratamento de doenças oculares
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
AR120655A1 (es) Anticuerpos ampliamente neutralizantes contra vih
MX385405B (es) Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.
ECSP21002804A (es) Apirasas solubilizadas, métodos y usos
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
DOP2024000117A (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
MX2021005910A (es) Formulacion de proteina de alta concentracion.
MX2017013879A (es) Composiciones que comprenden anakinra.
CL2022003349A1 (es) Composiciones de nanoemulsiones oftálmicas
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
MX2021004418A (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento.
MX2021013634A (es) Composiciones estables de albuvirtida.